274 related articles for article (PubMed ID: 22380010)
21. Polymeric micelles for oral drug administration enabling locoregional and systemic treatments.
Simões SM; Figueiras AR; Veiga F; Concheiro A; Alvarez-Lorenzo C
Expert Opin Drug Deliv; 2015 Feb; 12(2):297-318. PubMed ID: 25227130
[TBL] [Abstract][Full Text] [Related]
22. A timely reassessment of early prediction in the bioavailability of orally administered drugs.
Larsen T; Link A
Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039
[No Abstract] [Full Text] [Related]
23. Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route.
Choudhury H; Gorain B; Chatterjee B; Mandal UK; Sengupta P; Tekade RK
Curr Pharm Des; 2017; 23(17):2504-2531. PubMed ID: 27908273
[TBL] [Abstract][Full Text] [Related]
24. Ligand-mediated active targeting for enhanced oral absorption.
Zhang X; Wu W
Drug Discov Today; 2014 Jul; 19(7):898-904. PubMed ID: 24631680
[TBL] [Abstract][Full Text] [Related]
25. Intestinal transport as a potential determinant of drug bioavailability.
Nauli AM; Nauli SM
Curr Clin Pharmacol; 2013 Aug; 8(3):247-55. PubMed ID: 23343017
[TBL] [Abstract][Full Text] [Related]
26. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
27. BCS class IV drugs: Highly notorious candidates for formulation development.
Ghadi R; Dand N
J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
[TBL] [Abstract][Full Text] [Related]
28. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
Roger E; Lagarce F; Garcion E; Benoit JP
Nanomedicine (Lond); 2010 Feb; 5(2):287-306. PubMed ID: 20148639
[TBL] [Abstract][Full Text] [Related]
29. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
30. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
Porter CJ; Pouton CW; Cuine JF; Charman WN
Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
[TBL] [Abstract][Full Text] [Related]
31. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication.
Shahbazi MA; Santos HA
Curr Drug Metab; 2013 Jan; 14(1):28-56. PubMed ID: 22497568
[TBL] [Abstract][Full Text] [Related]
32. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.
Cho HJ; Kim JE; Kim DD; Yoon IS
Drug Dev Ind Pharm; 2014 Aug; 40(8):989-98. PubMed ID: 23981203
[TBL] [Abstract][Full Text] [Related]
33. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs.
Patel JP; Brocks DR
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1385-98. PubMed ID: 19663632
[TBL] [Abstract][Full Text] [Related]
34. Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrate.
Mizuma T
J Pharm Sci; 2008 Dec; 97(12):5471-6. PubMed ID: 18383337
[TBL] [Abstract][Full Text] [Related]
35. Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery.
Leonaviciute G; Bernkop-Schnürch A
Expert Opin Drug Deliv; 2015; 12(11):1703-16. PubMed ID: 26477549
[TBL] [Abstract][Full Text] [Related]
36. Nanocarriers protecting toward an intestinal pre-uptake metabolism.
Suchaoin W; Bernkop-Schnürch A
Nanomedicine (Lond); 2017 Feb; 12(3):255-269. PubMed ID: 28093952
[TBL] [Abstract][Full Text] [Related]
37. Polyaminoacid-based nanocarriers: a review of the latest candidates for oral drug delivery.
Robla S; Alonso MJ; Csaba NS
Expert Opin Drug Deliv; 2020 Aug; 17(8):1081-1092. PubMed ID: 32478584
[TBL] [Abstract][Full Text] [Related]
38. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
39. Polymeric micelles for oral drug delivery.
Gaucher G; Satturwar P; Jones MC; Furtos A; Leroux JC
Eur J Pharm Biopharm; 2010 Oct; 76(2):147-58. PubMed ID: 20600891
[TBL] [Abstract][Full Text] [Related]
40. Lipopolysaccharide Nanosystems for the Enhancement of Oral Bioavailability.
Sumaila M; Marimuthu T; Kumar P; Choonara YE
AAPS PharmSciTech; 2021 Sep; 22(7):242. PubMed ID: 34595578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
